Key facts
- It has raised $5.4M; the latest was Later Stage VC ($5.0M) in Jan 2025.
- Notable investors include National Institutes of Health, Biolocity, Georgia Research Alliance, Orient Europharma Company.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cambium Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Cambium Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cambium Oncology
Developer of immuno-oncology therapeutics designed to provide small-molecule peptide drugs to activate the immune system to treat cancer. The company's therapeutics offer checkpoint inhibitor peptides that improve the anti-tumor activity in multiple models, including pancreatic cancer, melanoma, and leukemia, enabling patients to have improved anti-tumor activity in multiple models.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2018
- Employees
- 3
- Website
- cambiumoncology.com/
- Ownership
- Privately Held (backing)
Cambium Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambium Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambium Oncology in its N-PORT filings yet. We sweep new filings monthly.